U.S. Software Stock News

In recent months, Green Brick Partners announced that several of its master-planned communities were ranked among the top developments nationally and in North Texas by John Burns Research and Consulting, RCLCO, and the Dallas Business Journal, while the company was recognized as the number three homebuilder in North Texas by new home closings. This cluster of independent accolades underscores Green Brick’s strong execution in key Sunbelt markets and highlights the scale of its presence in...

Why Microvast’s New Finance Leadership Matters for Investors Microvast Holdings (MVST) has refreshed its senior finance team, naming interim finance lead Rodney Worthen as Chief Financial Officer and hiring former NextDecade executive Eric N. Garcia as Chief Accounting Officer. These appointments concentrate financial reporting, planning, and corporate development experience at the top of Microvast’s battery and energy storage business, which already reports annual revenue of US$444.5 million...

In December 2025, Federal Agricultural Mortgage completed a US$313.5 million securitization of agricultural mortgage loans, signaling continued investor appetite for its farm and rural credit exposure despite recent macro volatility. This transaction highlights how the company can recycle capital from its Farm & Ranch and related portfolios to support future lending capacity across rural America. Next, we’ll explore how this securitization and improving monetary conditions could influence...

Recent financial media coverage has pushed LexinFintech Holdings (LX) into the spotlight as a penny stock candidate, with attention centering on its fundamentals and its role within consumer finance during broader market volatility. See our latest analysis for LexinFintech Holdings. Despite the recent media spotlight, LexinFintech Holdings has faced pressure, with a 90 day share price return of a 40.12% decline and a 1 year total shareholder return of a 54.17% decline, suggesting momentum has...

Spire Global (SPIR) is back in focus after the company launched nine satellites on SpaceX's Twilight mission, including its HyMS weather sensor and eight satellites supporting Myriota's global IoT connectivity network. See our latest analysis for Spire Global. That satellite launch comes on the back of a sharp swing in sentiment, with a 72.51% 30 day share price return and a 55.06% year to date share price return, even though the 1 year total shareholder return is still a 32.65% decline. If...

In early January 2026, STAG Industrial’s board approved a first‑quarter 2026 dividend of US$0.3875 per share, raising the annual rate from US$1.49 to US$1.55 and moving from monthly to quarterly payments, with a record date of March 31 and payment on April 15. This dividend increase, alongside mixed analyst opinions and strong leasing progress into 2025 and 2026, adds a new layer to how investors may view STAG Industrial’s income profile and growth plans. Now we’ll explore how the dividend...

Curtiss-Wright (CW) recently partnered with Green Hills Software to launch a safety-certifiable COTS computing platform for aerospace and defense, raising fresh questions about how this product expansion aligns with the stock’s strong recent returns. See our latest analysis for Curtiss-Wright. The Green Hills collaboration arrives during a strong run for Curtiss-Wright, with a 24.41% 30-day share price return and a 21.77% 90-day share price return. The 1-year total shareholder return of...

Earlier this month, FuelCell Energy ended the employment of its Executive Vice President, General Counsel and Corporate Secretary Joshua Dolger without cause, and appointed Amanda J. Schreiber to those roles effective January 12, 2026. Schreiber’s extensive experience guiding complex power projects, governance, and risk management at ContourGlobal brings a power-sector-focused legal and compliance perspective to FuelCell Energy’s leadership team. Next, we’ll examine how Schreiber’s...

Latest Earnings Snapshot and How It Fits the Story Regions Financial (RF) has wrapped up FY 2025 with fourth quarter revenue of US$1,806 million and EPS of US$0.59, alongside trailing 12 month revenue of US$7.1 billion and EPS of US$2.31 that frame the full year picture. Over recent quarters the company has seen revenue move from US$1,660 million in Q1 2025 to US$1,811 million in Q3 2025, and EPS range between US$0.51 and US$0.62. This gives investors a clear line of sight on how the top line...

Morgan Stanley recently named Regency Centers its top REIT pick, emphasizing the company’s grocery-anchored shopping centers in high-income, densely populated suburban markets and its outlook for funds from operations growth through 2027. The appointment of Equity Residential CEO Mark J. Parrell to Regency Centers’ board from January 2026 adds cross-sector real estate expertise that could influence future capital allocation and portfolio decisions. Now we’ll examine how Morgan Stanley’s...

If you are wondering whether Ziff Davis is a bargain or a value trap at its current US$37.48 share price, you are not alone. The stock has returned 3.6% over the last 7 days and 4.8% over the last 30 days. Year to date it is at 10.3%, with a 31.8% decline over 1 year and a 56.1% decline over 3 years. These mixed returns sit against an ongoing stream of corporate updates and portfolio activity that continue to keep Ziff Davis on investors' watchlists. Together, these developments help explain...

Conference spotlight and why investors are watching LightPath Technologies (LPTH) is set to present at the 28th Annual Needham Growth Conference at The Lotte New York Palace Hotel in New York, and that upcoming appearance is drawing fresh attention from investors. See our latest analysis for LightPath Technologies. That conference appearance comes after a sharp run in the shares, with a 30 day share price return of 82.70% and a 1 year total shareholder return of 273.00%. This suggests...

Why EVERTEC (EVTC) is on investors’ radar today EVERTEC (EVTC) has drawn investor attention after its latest financial metrics highlighted solid transaction processing activity across Latin America and the Caribbean, with annual revenue of US$903.381m and net income of US$146.091m. Those headline figures, combined with mixed recent share returns and an assigned value score of 5, are prompting investors to reassess how this regional payments and fintech provider fits into a diversified...

Wondering if UMB Financial at around US$122 per share is offering fair value right now, or if the price is leaving some upside on the table for patient investors? The stock has recently shown steady returns, with about 0.4% over the last week, 2.6% over the last month, 4.8% year to date and 3.6% over the past year, adding to longer term returns of 51.2% over three years and 76.6% over five years. Recent coverage of UMB Financial has focused on how investors are reassessing bank stocks more...

If you are wondering whether AdaptHealth's share price lines up with its underlying worth, you are not alone. This article focuses squarely on what the current price might be implying about value. The stock last closed at US$10.61, with returns of 1.1% over 7 days, 1.2% over 30 days, 9.7% year to date and 0.9% over 1 year. These figures are set against much weaker 3 year and 5 year returns of 49.5% and 72.1% declines. Recent coverage has focused on AdaptHealth's position in the home...

If you are wondering whether W.W. Grainger at around US$1,068.72 is priced for strength or stretched, you are not alone. This article is built to help you frame that question clearly. The stock has returned 3.8% over the last 7 days, 4.8% over the last 30 days, 6.5% year to date, but shows a 3.2% decline over the last year, while longer periods such as 3 years and 5 years sit at 96.0% and 187.0% respectively. Recent coverage of W.W. Grainger has centered on its role as a key industrial...

Why Marqeta’s New CFO Matters for Investors Marqeta (MQ) has appointed Patti Kangwankij as Chief Financial Officer, effective February 9, 2026. This leadership change puts an experienced technology and payments executive at the center of its financial decision making. See our latest analysis for Marqeta. Despite the CFO appointment setting a fresh tone for execution, Marqeta’s recent 30 day share price return of 9.35% and year to date share price return of 3.88% are weaker, while the 1 year...

BlackRock (BLK) has wrapped up FY 2025 with fourth quarter revenue of US$7.0b and basic EPS of US$7.26, while trailing 12 month figures show revenue of US$24.2b and EPS of US$35.83. Over recent periods, revenue has moved from US$20.4b in the trailing 12 months to Q4 2024 to US$24.2b by Q4 2025, with basic EPS shifting from US$42.45 to US$35.83 over the same comparison window. With trailing net profit margin at 22.9%, down from 31.2% a year earlier, the latest results pair solid top line...

If you are wondering whether Somnigroup International at around US$94 is priced for perfection or still offers value, this breakdown will help you frame that question clearly. The share price comes with a 0.2% return over the last 7 days, 5.6% over 30 days, 5.9% year to date and 59.0% over the past year, with a 3 year return of 152.1% and 5 year return of 243.0% that many investors will want to put into context. Recent coverage has focused on Somnigroup International's position within its...

Why Compass Therapeutics Is On Investors’ Radar Compass Therapeutics (CMPX) has drawn attention after recent share price moves, with the stock showing double digit returns over the past month and past 3 months despite reporting a net loss and no revenue. See our latest analysis for Compass Therapeutics. At a share price of $5.70, Compass Therapeutics has a 30 day share price return of 14.92% and a 90 day share price return of 33.80%. Its 1 year total shareholder return of 119.23% suggests...

Arcus Biosciences recently outlined its 2026 priorities, highlighting multiple planned clinical data readouts for casdatifan in clear cell renal cell carcinoma and progress across its inflammation and immunology programs. The company also emphasized advancement of quemliclustat in a registrational Phase 3 trial for first-line pancreatic cancer, with results expected in the first half of 2027, underscoring a pipeline that is moving into potentially registration-enabling territory across more...

Mereo BioPharma Group (NasdaqCM:MREO) has come into focus after releasing mixed Phase 3 results for setrusumab in osteogenesis imperfecta, along with a cash runway update to mid-2027 and progress on its alvelestat and vantictumab programs. See our latest analysis for Mereo BioPharma Group. The mixed Phase 3 readout and cash runway update come after a volatile stretch for the stock, with a 7 day share price return of 29.45% following a 30 day share price return decline of 66.67%, and a 1 year...

Rigel Pharmaceuticals (RIGL) has drawn fresh attention after launching a Phase 1b/2 trial combining REZLIDHIA with other therapies for acute myeloid leukemia and issuing full year 2026 revenue guidance of US$275 million to US$290 million. See our latest analysis for Rigel Pharmaceuticals. Despite the latest clinical update and 2026 revenue guidance, Rigel Pharmaceuticals’ recent share price performance has cooled, with a 7 day share price return of 8.23% and a 30 day share price return of...

Private Bancorp of America (PBAM) has wrapped up FY 2025 with fourth quarter revenue of US$29.9 million and basic EPS of US$1.75, alongside trailing twelve month revenue of US$119.2 million and EPS of US$7.09. Over recent periods, the company has seen quarterly revenue move from US$26.8 million in Q3 2024 to just over US$30.5 million in Q2 2025, with quarterly EPS ranging from about US$1.64 to US$1.83 over that span. This sets a clear earnings base for investors to work from. With a trailing...